Camp4 Therapeutics Corporation (NasdaqGM: CAMP)
Health Care · Biotechnology · US
$4.34
-20.22% today · +192.5% 1Y
Camp4 Therapeutics Corporation (NasdaqGM: CAMP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $341.38M and employs 48 people.
Over the last twelve months the share price has gained 192.5%, trading between 1.32 and 7.75.
Tweenvest scores Camp4 Therapeutics Corporation across four factors: quality 21/100, value 65/100. Its strongest factor is value.
CAMP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $341.38M
- Revenue (TTM)
- $4.22M
- P/E
- —
- EPS
- -2.17
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $7.75
- 52-week low
- $1.32
- Avg volume (3M)
- —
- Shares outstanding
- 62.75M
- Employees
- 48
- Next earnings
- —
About Camp4 Therapeutics Corporation
CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.
- ISIN
- US13463J1016
- Founded
- 2015
- Listed since
- Oct 11, 2024
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.42 | -1.27% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.10 | -0.48% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.70 | -0.05% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.79 | -0.55% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $822.15 | -1.37% |
| argenx SEENXTBR: ARGX | $64.17B | €889.60 | +1.18% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.44 | -5.91% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.